NALDEBAIN Trademark

Trademark Overview


On Thursday, November 2, 2023, a trademark application was filed for NALDEBAIN with the United States Patent and Trademark Office. The USPTO has given the NALDEBAIN trademark a serial number of 98251981. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, July 1, 2024. This trademark is owned by LUMOSA THERAPEUTICS CO., LTD.. The NALDEBAIN trademark is filed in the Pharmaceutical Products category with the following description:

Pain relief medication
naldebain

General Information


Serial Number98251981
Word MarkNALDEBAIN
Filing DateThursday, November 2, 2023
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateMonday, July 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateTuesday, August 6, 2024

Trademark Statements


Description of MarkThe mark consists of the stylized wording "NALDEBAIN".
Goods and ServicesPain relief medication
Indication of Colors claimedColor is not claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 20, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameLUMOSA THERAPEUTICS CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressTAIPEI CITY 11560
TW

Trademark Events


Event DateEvent Description
Monday, November 6, 2023NEW APPLICATION ENTERED
Monday, November 20, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 13, 2024ASSIGNED TO EXAMINER
Thursday, June 27, 2024APPROVED FOR PUB - PRINCIPAL REGISTER

Related Keywords


naldebain medication relief pain